| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.02 |